C. Intenzo, Aishwarya Gulati, Gabriela Bober, S. Jabbour, Jeffrey L. Miller, Intekab Ahmed, K. Furlong, S. Kim, Christine Wu, D. Capuzzi, J. Bilezikian
{"title":"在骨质减少患者中，骨矿物质密度的显著间歇下降并不是FRAX报告的一部分","authors":"C. Intenzo, Aishwarya Gulati, Gabriela Bober, S. Jabbour, Jeffrey L. Miller, Intekab Ahmed, K. Furlong, S. Kim, Christine Wu, D. Capuzzi, J. Bilezikian","doi":"10.54235/27382737-2022.v2.1-44","DOIUrl":null,"url":null,"abstract":"Background: Bone mineral density (BMD), considered to be a gold standard for the diagnosis of osteoporosis, is most commonly measured by dual-energy x-ray absorptiometry (DXA). For patients with osteopenia, the Fracture Risk Assessment Tool (FRAX) incorporates acknowledged other risk factors to assess overall fracture risk and aids in patient management. If the FRAX score in an osteopenic patient predicts a 10-year fracture risk of >20% for a major osteoporotic fracture or >3% for a hip fracture, pharmacologic therapy is indicated. However, FRAX does not include an assessment of a significant decline in BMD over time.","PeriodicalId":117806,"journal":{"name":"Armenian Journal of Health & Medical Sciences","volume":"41 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A significant interval decline in bone mineral density in osteopenic patients is not part of the FRAX report\",\"authors\":\"C. Intenzo, Aishwarya Gulati, Gabriela Bober, S. Jabbour, Jeffrey L. Miller, Intekab Ahmed, K. Furlong, S. Kim, Christine Wu, D. Capuzzi, J. Bilezikian\",\"doi\":\"10.54235/27382737-2022.v2.1-44\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Bone mineral density (BMD), considered to be a gold standard for the diagnosis of osteoporosis, is most commonly measured by dual-energy x-ray absorptiometry (DXA). For patients with osteopenia, the Fracture Risk Assessment Tool (FRAX) incorporates acknowledged other risk factors to assess overall fracture risk and aids in patient management. If the FRAX score in an osteopenic patient predicts a 10-year fracture risk of >20% for a major osteoporotic fracture or >3% for a hip fracture, pharmacologic therapy is indicated. However, FRAX does not include an assessment of a significant decline in BMD over time.\",\"PeriodicalId\":117806,\"journal\":{\"name\":\"Armenian Journal of Health & Medical Sciences\",\"volume\":\"41 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Armenian Journal of Health & Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54235/27382737-2022.v2.1-44\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Armenian Journal of Health & Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54235/27382737-2022.v2.1-44","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A significant interval decline in bone mineral density in osteopenic patients is not part of the FRAX report
Background: Bone mineral density (BMD), considered to be a gold standard for the diagnosis of osteoporosis, is most commonly measured by dual-energy x-ray absorptiometry (DXA). For patients with osteopenia, the Fracture Risk Assessment Tool (FRAX) incorporates acknowledged other risk factors to assess overall fracture risk and aids in patient management. If the FRAX score in an osteopenic patient predicts a 10-year fracture risk of >20% for a major osteoporotic fracture or >3% for a hip fracture, pharmacologic therapy is indicated. However, FRAX does not include an assessment of a significant decline in BMD over time.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
